Physician profile
Christopher Mitchell
NPI 1932317880
$4,815.05
in general payments reported to CMS, 2019-2025
45 companies · $23.16 in 2025
The $23.16 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $331 · 2021: $986 · 2022: $1,486 · 2023: $1,368 · 2024: $17.94 · 2025: $23.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $503.38 | 2019-2023 | |
| Celgene Corporation | $368.22 | 2021-2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $273.57 | 2019-2023 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $258.42 | 2019-2022 | |
| Sk Life Science, INC. | $222.62 | 2021-2023 | |
| Allergan, INC. | $218.64 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $146.73 | 2021-2023 | Rytary |
| Janssen Pharmaceuticals, INC | $142.01 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $135.48 | 2019-2024 | Nuplazid |
| Lundbeck LLC | $127.57 | 2020-2023 | Vyepti |
| Amgen INC. | $104.03 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.56 | 2020-2021 | |
| Argenx US, INC. | $85.91 | 2022-2023 | Vyvgart |
| Astrazeneca Pharmaceuticals LP | $79.57 | 2021-2023 | Andexxa |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.